Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
FOXO4-DRI
Preclinical
Research chemical
Summary
Synthetic D-retro-inverso peptide designed to disrupt FOXO4–p53 interaction, studied as a senolytic that selectively clears senescent cells in preclinical models.
Categories
Longevity
Mechanism
Blocks FOXO4 binding to p53, releasing p53 to trigger apoptosis preferentially in senescent cells that depend on FOXO4–p53 survival signaling. Designed as D-retro-inverso for protease resistance.
Half-life
Extended vs L-peptides due to D-amino acid design; exact human PK unknown
Routes
Subcutaneous injection
Legal / access
Experimental senolytic research peptide. Not approved for anti-aging use.
Key risks
- Transient inflammatory clearance effects
- Unknown long-term human safety
- High cost / purity variance across vendors
Common claims
- Cellular cleanup / senolytic cycles
- Longevity stack cornerstone
- Anti-frailty narratives
Select peptide B